About
Dr Andrew Warrilow is a protein biochemist working in the Centre for Cytochrome P450 Biodiversity (http://www.p450swansea.co.uk/) within Swansea University Medical School. He began his career at IACR Long Ashton Research Station near Bristol in 1995 before moving to the Wolfson Laboratory of Cytochrome P450 Biodiversity in Aberystwyth University during 1998 to work with Professor Steven Kelly and subsequently joined Swansea University in 2004.
Andrew's main research interests are sterol 14-alpha demethylases (CYP51) of fungal pathogens and their cytochrome P450 reductase (CPR) redox partners. Fungal CYP51 is the target enzyme of azole antifungal drugs and increasing resistance towards azole antifungals amongst clinical isolates of Candida spp., Aspergillus spp. and Mucorales necessitates greater understanding of azole resistance mechanisms and the synthesis and screening of new therapeutic agents to overcome this growing resistance.
Other research interests include the characterization of eukaryotic and prokaryotic cytochrome P450 monooxygenases, especially in terms of ligand binding, substrate specificity and enzyme kinetics; expertise shared with students enrolled on the taught modules Andrew contributes towards.
Andrew is a co-investigator on the BEACON (http://www.beaconwales.org) Biorefining Centre of Excellence programme. BEACON is a partnership between Aberystwyth, Bangor and Swansea Universities and the University of South Wales working in the field of conversion of biomass and biowastes into biobased products with commercial applications. BEACON is a £18.3 million project backed by the European Regional Development Fund through the Welsh Government and primarily aims to help Welsh businesses explore biobased opportunities for growth by providing access to wide-ranging specialist equipment and scientific expertise. BEACON won the 2014 RegioStars prize for the best Regional Project in the EU.